These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29871576)

  • 1. [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?].
    Lamy O; Gonzalez Rodriguez E; Stoll D; Aubry-Rozier B; Livio F
    Praxis (Bern 1994); 2018 Jun; 107(12):649-654. PubMed ID: 29871576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
    Jähn-Rickert K; Wölfel EM; Jobke B; Riedel C; Hellmich M; Werner M; McDonald MM; Busse B
    Front Endocrinol (Lausanne); 2020; 11():250. PubMed ID: 32499755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
    Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
    Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping Denosumab.
    Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
    Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second rebound-associated vertebral fractures after denosumab discontinuation.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
    Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
    De Sousa SMC; Jesudason D
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):250-252. PubMed ID: 30269340
    [No Abstract]   [Full Text] [Related]  

  • 8. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
    Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
    Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
    Tsourdi E; Langdahl B; Cohen-Solal M; Aubry-Rozier B; Eriksen EF; Guañabens N; Obermayer-Pietsch B; Ralston SH; Eastell R; Zillikens MC
    Bone; 2017 Dec; 105():11-17. PubMed ID: 28789921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
    Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
    Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
    Popp AW; Zysset PK; Lippuner K
    Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
    Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
    Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report.
    Mori Y; Izumiyama T; Mori N; Aizawa T
    Tohoku J Exp Med; 2021 May; 254(1):57-61. PubMed ID: 34053968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Denosumab in clinical practice : beware before, during and after].
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Aubry-Rozier B
    Rev Med Suisse; 2017 Apr; 13(559):863-866. PubMed ID: 28727345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
    Bandeira F; Torres G; Bandeira E; Duarte MB; Nóbrega AM; Bandeira L
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):163-166. PubMed ID: 30663978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
    Anastasilakis AD; Trovas G; Balanika A; Polyzos SA; Makras P; Tournis S
    J Clin Densitom; 2021; 24(2):338-340. PubMed ID: 33218880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
    Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
    Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.